Advertisment
Advicenne receives MHRA approval to market Sibnayal in the UK for the treatment of distal renal tubular acidosis
Advicenne announces that the Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Sibnayal (ADV 7103) in the UK, for the treatment of distal renal tubular acidosis (dRTA).
With this authorization,and following the recent approval by the European Commission to market Sibnayal for the treatment ofdRTA in the European Union, Advicenne is now able to bring to market in the EU and the UK the first and only label-approved drug for the treatment of dRTA in adults, adolescents and children aged one year and older.